Studies of Neurological Paraneoplastic Syndromes

Paraneoplastic Neurologic Degenerations (PNDs) Clinical Trial

Official title:

Studies of Neurological Paraneoplastic Syndromes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00587106
• Other study ID #: 88-044
• Status: Completed
• Phase: N/A
• First received: December 21, 2007
• Last updated: March 27, 2009
• Start date: April 1988
• Est. completion date: March 2009

Study information

• Verified date: March 2009
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Description:

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.

Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:

• analyzing for autoantibodies in serum and cerebral spinal fluid

• analyzing for antigen specificity and for antigens in cancer tissue

• comparing PND autoantibodies with those in cancer patients but no PND

• comparing PND autoantibodies with those in PND patients but no cancer

• studying the immune performance of patients with PNDs

As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adults are potentially eligible.

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Paraneoplastic Neurologic Degenerations (PNDs)
• Paraneoplastic Syndromes

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increase understanding of PNDS		Ongoing	No

External Links

•   Memorial Sloan-Kettering Cancer Center